Ethanol extract of Bupleurum falcatum and saikosaponins inhibit neuroinflammation via inhibition of NF-κB

Park, Wook Ha; Kang, Sung Un; Piao, Ying; Pak, Christine Jeehye; Oh, Myung Sook; Kim, Jinwoong; Kang, Min Sung; Pak, Youngmi Kim

doi:10.1016/j.jep.2015.07.039

Cited by 55 publications

(31 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Immunofluorescence staining was performed at room temperature according to previous studies [ 32 , 33 ]. Firstly, the cells were fixed by 4% paraformaldehyde (PFA, Sigma-Aldrich) and then permeabilized with 0.5% Triton X-100 (Sigma-Aldrich) solution in phosphate buffered saline (PBS) and incubated with blocking solution (3% bovine serum albumin (BSA, Sigma-Aldrich) diluted in 0.1% Triton X-100).…”

Section: Methodsmentioning

confidence: 99%

Osteopontin Promotes Expression of Matrix Metalloproteinase 13 through NF-κB Signaling in Osteoarthritis

Jiang

Wang

et al. 2016

BioMed Research International

View full text Add to dashboard Cite

Osteopontin (OPN) is associated with the severity and progression of osteoarthritis (OA); however, the mechanism of OPN in the pathogenesis of OA is unknown. In this study, we found that OA patients had higher abundance of OPN and matrix metalloproteinase 13 (MMP13). In chondrocytes, we showed that OPN promoted the production of MMP13 and activation of NF-κB pathway by increasing the abundance of p65 and phosphorylated p65 and translocation of p65 protein from cytoplasm to nucleus. Notably, inhibition of NF-κB pathway by inhibitor suppressed the production of MMP13 induced by OPN treatment. In conclusion, OPN induces production of MMP13 through activation of NF-κB pathway.

show abstract

Section: Methodsmentioning

confidence: 99%

Osteopontin Promotes Expression of Matrix Metalloproteinase 13 through NF-κB Signaling in Osteoarthritis

Jiang

Wang

et al. 2016

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…The report of Zhou et al [12] has also indicated that XFZYD seems to be able to alleviate hypoxia and protect liver sinusoidal endothelial cell function and does this by decreasing the levels of VEGF and HIF-1α. The formulation of XFZYD consists of eleven components (with respective representative active compounds in the bracket), namely Radix Angelicae Sinensis (Dang Gui: ferulic acid) [13, 14], Radix Rehmanniae glutinosae (Di Huang: catalpol) [15], Radix Paeoniae Rubra (Chi Shao: peoniflorin) [16], Rhizoma Ligustici Chuanxiong (Chuan Xiong: ferulic acid) [13, 14], Semen Pruni Persicae (Táo Rén: amygdalin) [17], Flos Carthami Tinctorii (Hong Hua: hydroxysafflor yellow A, HSYA) [18], Radix Glycyrrhizae Uralensis (Gan Cao: glycyrrhizin) [19], Fructus Auranti (Zhi Qiao: costunolide) [20], Radix Bupleuri Chinense (Chai Hu: saikosaponin) [21], Radix Achyranthis Bidentatae (Niu Xi: Achyranthes bidentata polysaccharides) [22], and Radix Platycodi Grandiflori (Jie Geng: platycodins) [23]. The important known effects of the defined active compounds described above are as follows.…”

Section: Introductionmentioning

confidence: 99%

“…Catalpol and the Achyranthes bidentata polysaccharides have antioxidative potential [15, 22]. Peoniflorin [16], amygdalin [17], HSYA [18], glycyrrhizin [19], costunolide [20] and saikosaponin [21] are able to protect against brain ischemia. Furthermore, amygdalin and HSYA have been shown to act additively by decreasing plasma viscosity and platelet aggregation.…”

Section: Introductionmentioning

confidence: 99%

Xue-fu-Zhu-Yu decoction protects rats against retinal ischemia by downregulation of HIF-1α and VEGF via inhibition of RBP2 and PKM2

Tan

Geng

Liu

et al. 2017

BMC Complement Altern Med

View full text Add to dashboard Cite

BackgroundRetinal ischemia-related eye diseases result in visual dysfunction. This study investigates the protective effects and mechanisms of Xue-Fu-Zhu-Yu decoction (XFZYD) with respect to retinal ischemia.MethodsRetinal ischemia (I) was induced in Wistar rats by a high intraocular pressure (HIOP) of 120 mmHg for 1 h, which was followed by reperfusion of the ischemic eye; the fellow untreated eye acted as a control. Electroretinogram (ERG), biochemistry and histopathology investigations were performed.ResultsSignificant ischemic changes occurred after ischemia including decreased ERG b-wave ratios, less numerous retinal ganglion cells (RGCs), reduced inner retinal thickness, fewer choline acetyltransferase (ChAT) labeled amacrine cell bodies, increased glial fibrillary acidic protein (GFAP) immunoreactivity and increased vimentin Müller immunolabeling. These were accompanied by significant increases in the mRNA/protein concentrations of vascular endothelium growth factor, hypoxia-inducible factor-1α, pyruvate kinase M2 and retinoblastoma-binding protein 2. The ischemic changes were concentration-dependently and significantly altered when XFZYD was given for seven consecutive days before or after retina ischemia, compared to vehicle. These alterations included enhanced ERG b-wave amplitudes, more numerous RGCs, enhanced inner retinal thickness, a greater number of ChAT immunolabeled amacrine cell bodies and decreased GFAP/vimentin immunoreactivity. Furthermore, decreased mRNA levels of VEGF, HIF-1α, PKM2, and RBP2 were also found. Reduced protein concentrations of VEGF, HIF-1α, PKM2, and RBP2 were also demonstrated. Furthermore, there was an inhibition of the ischemia-associated increased ratios (target protein/β-actin) in the protein levels of VEGF, HIF-1α, PKM2, and RBP2, which were induced by Shikonin, JIB-04 or Avastin.ConclusionXFZYD would seem to protect against well-known retinal ischemic changes via a synergistic inhibition of RBP2 and PKM2, as well as down-regulation of HIF-1α and a reduction in VEGF secretion.Electronic supplementary materialThe online version of this article (doi:10.1186/s12906-017-1857-2) contains supplementary material, which is available to authorized users.

show abstract

“…A positron emission tomography-based study demonstrated that findings suggestive of neuroinflammation existed in several cerebral areas in patients with ME/CFS (5). Among the seven herbal ingredients in SST, Bupleurum falcatum root (BR) and Scutellaria baicalensis root (SR) are reportedly effective in (6). Reportedly, SR extract reduces brain damage by suppressing the production of inflammatory cytokines (e.g., tumor necrosis factor-α, interleukin-6) and regulating glial-cell activity in the striatum in a dosedependent manner (7).…”

Section: Discussionmentioning

confidence: 99%

Successful Treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome with Chronic Febricula Using the Traditional Japanese Medicine Shosaikoto

Numata

Miura²,

Akaishi

et al. 2020

Intern. Med.

View full text Add to dashboard Cite

We herein report the case of a 14-year-old girl who had been experiencing chronic fatigue, febricula, and social withdrawal for 20 months. No notable abnormalities were identified during routine checkups at a general pediatric hospital; symptomatic treatments did not affect her condition. She was diagnosed with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Based on the concepts of Japanese traditional medicine, she was administered shosaikoto-based treatment. After several weeks of treatment, all of the symptoms had been dramatically alleviated, consequently resolving the issue of non-attendance at school. Shosaikotobased medication may be a therapeutic option for treating ME/CFS in patients presenting with chronic febricula.

show abstract

Ethanol extract of Bupleurum falcatum and saikosaponins inhibit neuroinflammation via inhibition of NF-κB

Cited by 55 publications

References 37 publications

Osteopontin Promotes Expression of Matrix Metalloproteinase 13 through NF-κB Signaling in Osteoarthritis

Osteopontin Promotes Expression of Matrix Metalloproteinase 13 through NF-κB Signaling in Osteoarthritis

Xue-fu-Zhu-Yu decoction protects rats against retinal ischemia by downregulation of HIF-1α and VEGF via inhibition of RBP2 and PKM2

Successful Treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome with Chronic Febricula Using the Traditional Japanese Medicine Shosaikoto

Contact Info

Product

Resources

About